Loading
Life sciences · Journal article
Journal of Human Immunity · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
While autoantibodies (auto-Abs) neutralizing type I interferons (IFN-I) are relatively rare before the age of 65 (<1%), their prevalence reaches 2-3% between 70 and 80 years and >6% in individuals above 80 years in the general population. To assess the prevalence of IFN-I auto-Abs at the extreme end of human lifespan, we performed a multinational study of centenarians from four geographically and ethnically distinct cohorts collected in Denmark (n = 258), Colombia (n = 99), Australia (n = 281), and Japan (n = 300), comprising 938 individuals. Across cohorts, 51/938 centenarians (5.4%) harbored auto-Abs neutralizing IFN-I, ranging from 3.3% (Japan) to 9.1% (Colombia). We found that the prevalence of IFN-I auto-Abs levels off in centenarians compared with individuals ≥80 years from the general population, demonstrating that neutralizing IFN-I auto-Abs are not incompatible with longevity, despite conferring a risk of life-threatening viral infections. Yet, the plateau of their prevalence in centenarians suggests that they may not be beneficial for reaching exceptional longevity and may negatively impact mortality.